Advances in Immunotherapy in Esophagogastric Cancer.
Hematol Oncol Clin North Am
; 38(3): 599-616, 2024 06.
Article
em En
| MEDLINE
| ID: mdl-38493074
ABSTRACT
Immune checkpoint inhibitors are rapidly transforming the care of patients with esophagogastric cancer. Particularly, anti-PD-1 therapy has demonstrated promising efficacy in metastatic and resectable disease. In this review, the authors discuss landmark clinical trials, highlight challenges and opportunities in this field, and propose potential directions for future work.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Gástricas
/
Neoplasias Esofágicas
/
Inibidores de Checkpoint Imunológico
/
Imunoterapia
Limite:
Humans
Idioma:
En
Revista:
Hematol Oncol Clin North Am
Assunto da revista:
HEMATOLOGIA
/
NEOPLASIAS
Ano de publicação:
2024
Tipo de documento:
Article
País de publicação:
Estados Unidos